Automated radiosynthesis of [¹⁸F]DPA-714 on a commercially available IBA Synthera®

The goal of this work was to develop a reliable method to produce the well-validated microglial activation PET tracer, [¹⁸F]DPA-714, routinely for clinical and preclinical research using an IBA Synthera®. Optimization of literature methods included reduced precursor mass and use of TBA HCO₃ as the phase transfer agent in place of Kryptofix® 222 in a 65-min synthesis with an average activity yield of 24.6 ± 3.8% (n = 5). Successful quality control testing and process validation results are reported.